Manchester City came from behind against Club Brugge to reach the Champions League knockout phase, where they were safely ...

As the company faces criticism for its decision last year to not renew insurance policies for 72,000 property owners in California, State Farm has nixed plans to run a commercial during this year ...

Copyright 2025 The Associated Press. All Rights Reserved. Leverkusen’s head coach Xabi Alonso looks on ahead of the German Bundesliga soccer match between Borussia ...

Are you a print subscriber? Activate your account. By Ewan Larkin - 2 hours 3 min ago By Ad Age and Creativity Staff - 3 hours 56 min ago By Ad Age Staff - 4 hours 7 min ago By E.J. Schultz - 5 ...

JPM25: After BridgeBio touts 'remarkable' early uptake for its Vyndaqel rival, analysts hail Attruby's debut as a 'launch to own' Bayer will leverage its existing commercial infrastructure to ...

In a significant legal development, a jury in Washington has ordered Bayer to pay $100 million in damages to four individuals who claim their health was irreparably harmed by PCBs at a Seattle-area ...

Bayer AG’s Monsanto unit stopped making toxic PCBs a half century ago, but the legal fallout lingers even as many of the building materials made with the chemicals are no longer used in US homes ...

Trial was the latest over harm tied to school outside Seattle Company vows appeal of verdict and ‘excessive’ damages awarded Bayer AG was told by a jury to pay $100 million to four people at a Seattle ...

Jury Rules Bayer (Monsanto) Must Pay $100M in Trial Over PCBs in Washington School. Bayer has been ordered to pay $100 million to four individuals who claim they suffered health issues due to exposure ...

Bayer argues PCB levels were safe, blames school for ignoring warnings Previous trials resulted in over $1.5 billion in verdicts Jan 14 (Reuters) - A Washington jury on Tuesday ordered Bayer ...

Bayer expects its pharmaceutical business to return to growth in 2027, unit President Stefan Oelrich said Monday. The German conglomerate is planning to launch new therapies — one that treats a ...

Bayer’s Parkinson’s disease cell therapy is moving into late-stage testing, with the upcoming trial set to be the first registrational phase 3 study for an investigational allogeneic cell ...